 announced that global pharmaceutical firm Eli Lilly and Company (NYSE: LLY) is transferring select activities to support its U.S. clinical trials, including the areas of U.S. medical writing and biostatistical services, to i3 as part of Lilly’s continuing effort to transform its business in order to speed improved outcomes to individual patients.  This move marks a significant expansion of the business relationship between the two organizations since Lilly transferred the majority of its U.S. data management operations to i3 in 2008.
 
This agreement builds on i3’s steady growth in the area of functional service provision (FSP), having composed and deployed successful FSP teams throughout the industry since 1999. 
 
Life science companies have found that partnering with service providers in functional areas, such as information sciences—including data management, medical writing, and biostatistical services—enhances efficiencies, improves quality, and reduces costs.  

“i3, with an established presence on the north side of Indianapolis, has proved itself as a partner capable of consistently delivering high-quality work within our agreed-upon performance metrics,” said Aarti Shah, Ph.D., vice president statistics and advanced analytics hub, Eli Lilly and Company.
